Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10367375 | 0.89 | MAPT (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL5907891 | 0.88 | MTNR1A (0.45) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL184552 | 0.84 | MAPT (0.57) | MAPTTSHRHSD17B2ALDH1A1KDM4E | |
| SCHEMBL27705109 | 0.84 | KDM4E (0.46) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL3526985 | 0.82 | CA12 (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL11700738 | 0.82 | HTR2A (0.43) | MAPTTSHRHSD17B2NR1H4ALDH1A1 | |
| SCHEMBL12252482 | 0.81 | KDM4E (0.43) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL11238694 | 0.81 | TSHR (0.61) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL14859175 | 0.81 | GABRA1 (0.41) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL2480129 | 0.81 | STAT3 (0.41) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108084077-B | Synthetic method of zafirlukast intermediate | 江汉大学 | 2020-04-14 | — | — | CN | disclosed |
| CN-108084077-A | A kind of synthetic method of zafirlukast intermediate | 江汉大学 | 2018-05-29 | — | — | CN | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-0290145-B1 | Aliphatic carboxamides | ICI AMERICA INC (US) | 1994-10-26 | — | — | EP | disclosed |
| US-5234942-A | Treating allergic pulmonary disorders, asthma | ICI AMERICAS INC. (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0242167-B1 | HETEROCYCLIC CARBOXAMIDES | ICI AMERICAS INC. (US) | 1991-11-27 | — | — | EP | disclosed |
| US-4997844-A | Compounds for the treatment of allergic or inflammatory diseases or shock conditions | ICI AMERICAS INC. (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0179619-B1 | HETEROCYCLIC AMIDES | ICI AMERICAS INC. (US) | 1990-09-05 | — | — | EP | disclosed |
| US-4898863-A | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1990-02-06 | — | — | US | disclosed |
| US-4894386-A | ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1990-01-16 | — | — | US | disclosed |
| CN-1030910-A | ALIPHATIC CARBOXAMIDEX | ICI AMERICA INC (US) | 1989-02-08 | — | — | CN | disclosed |
| EP-0290145-A1 | Aliphatic carboxamides | ZENECA INC. (US) | 1988-11-09 | — | — | EP | disclosed |
| EP-0242167-A2 | Heterocyclic carboxamides | ICI AMERICAS INC. (US) | 1987-10-21 | — | — | EP | disclosed |
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | GABRA1 3031/4885GABRG2 3579/4885GABRB3 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.